相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Metabolomics reveals trichloroacetate as a major contributor to trichloroethylene-induced metabolic alterations in mouse urine and serum
Zhong-Ze Fang et al.
ARCHIVES OF TOXICOLOGY (2013)
Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver
Rainer Lehmann et al.
DIABETES CARE (2013)
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis
Naoki Tanaka et al.
HEPATOLOGY (2012)
Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method
Juan C. Garcia-Canaveras et al.
JOURNAL OF LIPID RESEARCH (2012)
Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis
Fei Li et al.
JOURNAL OF LIPID RESEARCH (2012)
Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs
Aiming Liu et al.
VASCULAR PHARMACOLOGY (2012)
Biphasic Regulation of Intracellular Calcium by Gemfibrozil Contributes to Inhibiting L6 Myoblast Differentiation: Implications for Clinical Myotoxicity
Aiming Liu et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2011)
Lithocholic Acid Disrupts Phospholipid and Sphingolipid Homeostasis Leading to Cholestasis in Mice
Tsutomu Matsubara et al.
HEPATOLOGY (2011)
Nuclear Receptors in Liver Disease
Martin Wagner et al.
HEPATOLOGY (2011)
Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats
Aiming Liu et al.
PHARMACOLOGICAL REPORTS (2011)
The fibrate drug gemfibrozil disrupts lipoprotein metabolism in rainbow trout
John S. Prindiville et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2011)
Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches
Gideon M. Hirschfield et al.
GASTROENTEROLOGY (2010)
Effects of the PPAR alpha Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism
Michael L. Cunningham et al.
PPAR RESEARCH (2010)
Combination therapy of statins and fibrates in the management of cardiovascular risk
Catherine Fievet et al.
CURRENT OPINION IN LIPIDOLOGY (2009)
Acute cholestatic hepatitis induced by fenofibrate
D. Hajdu et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry
Peiyuan Yin et al.
MOLECULAR BIOSYSTEMS (2009)
Myotoxicity of gemfibrozil in Cynomolgus monkey model and its relationship to pharmacokinetic properties
Aiming Liu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2009)
Relative safety of Gemfibrozil and Fenofibrate in the absence of concomitant Cerivastatin use
Noa Holoshitz et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis
Chi Chen et al.
CELL METABOLISM (2008)
The PPAR alpha-humanized mouse: A model to investigate species differences in liver toxicity mediated by PPAR alpha
Qian Yang et al.
TOXICOLOGICAL SCIENCES (2008)
The role of coenzyme Q10 in statin-associated myopathy - A systematic review
Leo Marcoff et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
High performance liquid chromatography-mass spectrometry for metabonomics: Potential biomarkers for acute deterioration of liver function in chronic hepatitis B
J Yang et al.
JOURNAL OF PROTEOME RESEARCH (2006)
Peroxisome proliferator-activated receptor-α and liver cancer:: where do we stand?
JM Peters et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
Role of peroxisome proliferator-activated receptor-alpha (PPAR alpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis
T Hays et al.
CARCINOGENESIS (2005)
Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients
N Roglans et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
DW Schneck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
C Kyrklund et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-α-mediated downregulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase expression
SM Post et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
The peroxisome proliferator-activated receptor α (PPARα) regulates bile acid biosynthesis
MC Hunt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
The murine and human cholesterol 7α-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor α
SK Cheema et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
